Adami HO, Graffman S, Johansson H, Rimsten Å: Survival and recurrences five years after selective treatment for breast carcinoma. Br J Cancer 38: 624–630, 1978Adami HO, Graffman S, Johansson H, Rimsan A (1978) Survival and recurrence five years after selective treatment for breast ...
Among patients who were recurrence-free when they stopped taking endocrine therapy after five years, the highest risk of recurrence was for those with originally large tumors and cancer that had spread to four or more lymph nodes. These women had a 40 percent risk of a distant cancer recurrence...
Occasionally, breast cancer relapses more than 5 years after initial treatment, sometimes with highly aggressive disease in such late-recurring patients. This study investigated predictors of recurrence after more than 5 years in operable breas
Breast Cancer Recurrence, Early Stage 1, 2 Breast Cancer Test, Prognostic Test For Breast Cancer In India, Tumour Test, Screening Test, Oncotype dx Test in India, CanAssistBreast, Oncostem, India
Lee et al. BMC Cancer (2016) 16:430 DOI 10.1186/s12885-016-2423-x RESEARCH ARTICLE Open Access Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer Eun-Shin Lee1, Wonshik Han1,6*, Min Kyoon Kim2, Jongjin Kim3...
Women with early-stage oestrogen receptor (ER)-positive (ER) breast cancer who receive standard endocrine therapy for 5 years remain at risk of distant recurrence for at least 15 years after treatment discontinuation. The extension of the duration of adjuvant endocrine therapy to 10 years has ...
breast cancer and has been shown to accurately predict the risk of the cancer spreading (metastasising) to other parts of the body within five or ten years. Women who were at low risk of a recurrence, based on these clinical and genomic factors, did not receive chemotherapy after surgery, ...
Occasionally, breast cancer relapses more than 5 years after initial treatment, sometimes with highly aggressive disease in such late-recurring patients. This study investigated predictors of recurrence after more than 5 years in operable breast cancer. We retrospectively analyzed data from patients with...
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. not indicated for adjuvant therapy beyond 5 years, the need for another therapy in the extended adjuvant setting to reduce late recurrence risk is clear... M Jahanzeb - 《Clinical Therapeut...
Patients with breast cancer recurrence in 2010 and 2011 with a previous breast cancer diagnosis were not included. The Lucien Neuwirth cancer institute is the unique cancer center of the Loire metropolitan area (corresponding to almost 800,000 inhabitants), and con- centrates all the patients ...